Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by azimexoneKREIENBERG, R; BOERNER, D; MELCHERT, F et al.Journal of immunopharmacology. 1983, Vol 5, Num 1-2, pp 49-64, issn 0163-0571Article

PREVENTION OF SPONTANEOUS TUMORS OF AGED MICE BY IMMUNOPHARMACOLOGIC MANIPULATION: STUDY OF IMMUNE ANTITUMOR MECHANISMSBRULEY ROSSET M; HERCEND T; MARTINEZ J et al.1981; J. NATL. CANCER INST.; ISSN 0027-8874; USA; DA. 1981; VOL. 66; NO 6; PP. 1113-1119; BIBL. 31 REF.Article

THERE NEW AGENTS FOR IMMUNOTHERAPY TRIALS: AZIMEXON, BESTATIN, AND TUFTSINMATHE G; FLORENTIN I; BRULEY ROSSET M et al.1982; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1982; NO 80; PP. 331-333; BIBL. 20 REF.Article

Immunopharmacologic bases of immunotherapyHADDEN, J. W; KESKINER MERRIAM, L.Clinical physiology and biochemistry. 1985, Vol 3, Num 2-3, pp 111-119, issn 0252-1164Article

INVESTIGATION IN MICE ON THE POTENTIATION OF RESISTANCE TO INFECTIONS BY A NEW IMMUNOSTIMULANT COMPOUNDBICKER U; ZIEGLER AE; HEBOLD G et al.1979; J. INFECT. DIS.; ISSN 0022-1899; USA; DA. 1979; VOL. 139; NO 4; PP. 389-395; BIBL. 16 REF.Article

L'EXPLORATION IMMUNITAIRE DU PATIENT CANCEREUX: CELLULES SUPPRESSIVES ET CELLULES NKGOUTNER A; THOMAS Y; HUCHET R et al.1980; C.R. SOC. BIOL. FIL.; ISSN 0037-9026; FRA; DA. 1980; VOL. 174; NO 4; PP. 750-755; ABS. ENG; BIBL. 14 REF.Article

REDUCTION OF ACUTE TOXICITY OF CYCLOPHOSPHAMIDE AND X-RAYS BY THE NEW IMMUNOMODULATING COMPOUND BM 12531BICKER U; FRIEDBERG KD; HEBOLD G et al.1979; EXPERIENTIA; CHE; DA. 1979; VOL. 35; NO 10; PP. 1361-1363; BIBL. 16 REF.Article

AN INTENSIVE CHEMO- OR CHEMOIMMUNOTHERAPY REGIMEN FOR PATIENTS WITH INTERMEDIATE AND POOR-PROGNOSIS ACUTE LYMPHATIC LEUKEMIA AND LEUKEMIC LYMPHOBLASTIC LYMPHOSARCOMA: PRELIMINARY RESULTS WITH 14-MONTH MEDIAN FOLLOW-UPMISSET JL; DE VASSAL F; DELGADO M et al.1982; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1982; NO 80; PP. 29-35; BIBL. 13 REF.Article

INFLUENCE OF ORAL BM 12531 (INN AZIMEXON) ON IMMUNE RESPONSE IN UNTREATED CANCER PATIENTS: A RANDOMIZED DOUBLE-BLIND STUDYHEIM ME; MASSNER B; KNEBEL L et al.1981; CANCER IMMUNOL. IMMUNOTHER.; ISSN 0340-7004; DEU; DA. 1981; VOL. 12; NO 1; PP. 87-90; BIBL. 12 REF.Article

PHARMACOKINETICS OF ¹⁴C-ACTIVITY AFTER THE ADMINISTRATION OF¹⁴C-AZIMEXONE IN RATSWOLFEL B; HARTUNG K; HAAK A et al.1981; INT. J. IMMUNOPHARMACOL.; ISSN 0192-0561; USA; DA. 1981; VOL. 3; NO 2; PP. 133-140; BIBL. 10 REF.Article

Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC)PATT, Y. Z; MANSELL, P. W. A; REUBEN, J. M et al.AIDS research. 1986, Vol 2, Num 3, pp 191-209, issn 0737-6006Article

IMMUNORESTORATION OF ANERGIC CANCER PATIENTS BY AZIMEXONGOUTNER A; NASRAT F; BONARDELLE D et al.1980; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1980; NO 75; PP. 47-52; BIBL. 5 REF.Article

EFFECTS OF BM 12,531 (AZIMEXON) ON IN VITRO LYMPHOCYTE AND MACROPHAGE PROLIFERATIONHADDEN JW; COFFEY RG.1980; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1980; NO 75; PP. 162-164; BIBL. 3 REF.Article

ENHANCED PHA STIMULATION OF CANCER PATIENTS' LYMPHOCYTES BY ADDITION OF BM 12531 (AZIMEXON) IN VITROCOLOT M; MICKSCHE M; BICKER U et al.1979; CANCER IMMUNOL. IMMUNOTHERAPY; DEU; DA. 1979; VOL. 6; NO 3; PP. 175-178; BIBL. 29 REF.Article

Low molecular weight immunopotentiatorsRUSZALA-MALLON, V; YANG-I LIN; DURR, F. E et al.International journal of immunopharmacology. 1988, Vol 10, Num 5, pp 497-510, issn 0192-0561Article

IMMUNOMODULATORY EFFECT OF VARIOUS MOLECULAR-WEIGHT MALEIC ANHYDRIDE-DIVINYL ETHERS AND OTHER AGENTS IN VIVOCHIRIGOS MA; STYLOS WA.1980; CANCER RES.; USA; DA. 1980; VOL. 40; NO 6; PP. 1967-1972; BIBL. 33 REF.Article

ETUDE DU MODE D'ACTION DE QUATRE NOUVELLES SUBSTANCES CHIMIQUEMENT DEFINIES AYANT DES PROPRIETES IMMUNOMODULATRICESMATHE GEORGES.1980; ; FRA; DA. 1980; DGRST/78 7 2651; 51 P.; 30 CM; BIBL. 19 REF.; ACTION CONCERTEE: CANCEROGENESE ET PHARMACOLOGIE DU CANCERReport

THERAPEUTIC EFFECTS OF BM 12,531 (PROP. INN AZIMEXON)BICKER U.1980; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1980; NO 75; PP. 147-152; BIBL. 6 REF.Article

INFLUENCE OF BM 12-531 (PROP. INN AZIMEXON) ON THE LYMPHOCYTE TRANSFORMATION AND THE PERCENTAGE OF ACTIVE T LYMPHOCYTES IN VIVO AND IN VITRO IN MANBOERNER D; BICKER U; ZIEGLER AE et al.1979; CANCER IMMUNOL. IMMUNOTHERAPY; DEU; DA. 1979; VOL. 6; NO 4; PP. 237-242; BIBL. 10 REF.Article

NEW IMMUNOMODULATING AGENTS AND BIOLOGICAL RESPONSE MODIFIERS. LECTURES PRESENTED ON SEPTEMBER 29, 1980, AT THE ERASME HOSPITAL, UNIVERSITY OF BRUSSELSSERROU B ED; ROSENFELD C ED; WYBRAN J ED et al.1982; HUMAN CANCER IMMUNOLOGY; ISSN 506273; NLD; DA. 1982; VOL. 3; XIII-164 P.; BIBL. DISSEM.Conference Paper

RESYNTHESIS OF TRYPSINIZED SHEEP RED BLOOD CELL RECEPTORS ON HUMAN LYMPHOCYTES: COMPARISON OF THE EFFECTS OF IMMUNOPOTENTIATORS OF BIOLOGICAL AND SYNTHETIC ORIGIN IN VITRONEKAM K; FUDENBERG HH; MANDI B et al.1981; IMMUNOPHARMACOLOGY; USA; DA. 1981; VOL. 3; NO 1; PP. 31-39; BIBL. 3 P.Article

IN VIVO IMMUNODULATING PROPERTIES OF TWO SYNTHETIC AGENTS: AZIMEXON AND TUFTSINFLORENTIN I; SCHULZ J; BRULEY ROSSET M et al.1980; RECENT RESULTS CANCER RES.; ISSN 0080-0015; USA; DA. 1980; NO 75; PP. 153-161; BIBL. 15 REF.Article

Effect of BM 12531 on in vitro induction of suppressor cells by concanavalin A in cancer patients and normal healthy donorsSOMASUNDARAM, R; ADVANI, S. H; SHETYE, M. R et al.Journal of clinical & laboratory immunology. 1986, Vol 19, Num 1, pp 43-47, issn 0141-2760Article

Modulation of myelopoiesis by CSF or CSF-inducing biological response modifiersSCHLICK, E; RUFFMANN, R; HARTUNG, K et al.Journal of immunopharmacology. 1985, Vol 7, Num 1, pp 141-166, issn 0163-0571Article

Structural studies of immunomodulators. II, Crystal structure and conformation of azimexon (BM 12.531) an immunostimulant and an anti-tumor drugSRIKRISHNAN, T.Anti-cancer drug design. 1990, Vol 5, Num 2, pp 213-220, issn 0266-9536Article